{"id":35143,"date":"2025-08-20T15:19:16","date_gmt":"2025-08-20T13:19:16","guid":{"rendered":"https:\/\/ggba.swiss\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/"},"modified":"2025-08-20T15:29:55","modified_gmt":"2025-08-20T13:29:55","slug":"pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/","title":{"rendered":"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.pilatusbio.com\/\">Pilatus Biosciences<\/a>, une soci\u00e9t\u00e9 biopharmaceutique install\u00e9e au <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le<\/a> \u00e0 \u00c9palinges (Vaud), a annonc\u00e9 le lancement de son premier essai clinique de Phase 1 chez l\u2019humain. L\u2019\u00e9tude testera le candidat principal de l\u2019entreprise, PLT012, en combinaison avec l\u2019atezolizumab (Tecentriq), fourni par Roche, chez des patients atteints de carcinome h\u00e9patocellulaire (CHC), le type le plus courant de cancer primitif du foie.<\/p>\n\n\n\n<p>Fond\u00e9e en 2022 \u00e0 la suite de recherches men\u00e9es au <a href=\"https:\/\/www.ludwigcancerresearch.org\/location\/lausanne\/\">Ludwig Institute for Cancer Research<\/a> et soutenue par le Cancer Research Institute, Pilatus d\u00e9veloppe des immunoth\u00e9rapies ciblant les points de contr\u00f4le m\u00e9taboliques afin de reprogrammer le microenvironnement tumoral (TME). Ses activit\u00e9s internationales de R&amp;D sont r\u00e9parties entre la Suisse et Ta\u00efwan, avec un accent particulier sur les cancers du foie et gastro-intestinaux.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Cibler le microenvironnement tumoral dans le cancer du foie<\/h4>\n\n\n\n<p>PLT012 est un anticorps monoclonal humanis\u00e9 con\u00e7u pour bloquer s\u00e9lectivement l\u2019absorption des lipides m\u00e9di\u00e9e par CD36, un m\u00e9canisme qui contribue \u00e0 l\u2019immunosuppression et \u00e0 la r\u00e9sistance aux traitements dans les tumeurs h\u00e9patiques. En ciblant le m\u00e9tabolisme lipidique, PLT012 vise \u00e0 rendre les tumeurs dites \u00ab froides \u00bb plus r\u00e9actives, renfor\u00e7ant ainsi l\u2019efficacit\u00e9 des inhibiteurs de points de contr\u00f4le immunitaire tels que les th\u00e9rapies anti\u2013PD-L1.<\/p>\n\n\n\n<p>Les \u00e9tudes pr\u00e9cliniques ont montr\u00e9 que PLT012 pr\u00e9sente une activit\u00e9 puissante en monoth\u00e9rapie dans des mod\u00e8les de cancer du foie, tout en agissant comme un puissant sensibilisateur lorsqu\u2019il est combin\u00e9 \u00e0 des inhibiteurs de points de contr\u00f4le. Cette double action sugg\u00e8re un potentiel \u00e0 la fois pour des effets antitumoraux directs et pour une meilleure r\u00e9activit\u00e9 aux th\u00e9rapies existantes.<\/p>\n\n\n\n<p>\u00ab Cette collaboration repr\u00e9sente une opportunit\u00e9 d\u2019explorer comment la modulation du microenvironnement tumoral peut renforcer le blocage des points de contr\u00f4le immunitaire dans le cancer du foie \u00bb, a d\u00e9clar\u00e9 le Dr Ann-Lii Cheng, professeur titulaire \u00e0 la NTU et pr\u00e9sident \u00e9m\u00e9rite du NTU Cancer Center de la National Taiwan University, et collaborateur scientifique de Pilatus. Le Dr Cheng a pr\u00e9c\u00e9demment \u00e9t\u00e9 l\u2019investigateur principal mondial de l\u2019essai clinique IMbrave150, qui a \u00e9tabli l\u2019atezolizumab associ\u00e9 au bevacizumab comme traitement de r\u00e9f\u00e9rence du CHC.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pilatus Biosciences \u00e9valuera son principal candidat en immunoth\u00e9rapie, PLT012, en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1 contre le cancer du foie.<\/p>\n","protected":false},"author":6,"featured_media":35147,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1188,1142,1168],"class_list":["post-35143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-healthcare-fr-2","tag-rd-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pilatus Biosciences lance son premier essai clinique chez l\u2019humain<\/title>\n<meta name=\"description\" content=\"Pilatus Biosciences va \u00e9valuer le PLT012 en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain\" \/>\n<meta property=\"og:description\" content=\"Pilatus Biosciences va \u00e9valuer le PLT012 en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T13:19:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T13:29:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain\",\"datePublished\":\"2025-08-20T13:19:16+00:00\",\"dateModified\":\"2025-08-20T13:29:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\"},\"wordCount\":388,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"keywords\":[\"Biotech\",\"Healthcare\",\"R&amp;D\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\",\"name\":\"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"datePublished\":\"2025-08-20T13:19:16+00:00\",\"dateModified\":\"2025-08-20T13:29:55+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Pilatus Biosciences va \u00e9valuer le PLT012 en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Ce nouvel essai clinique marque une \u00e9tape importante pour Pilatus Biosciences, qui fait progresser les immunoth\u00e9rapies de nouvelle g\u00e9n\u00e9ration de la recherche pr\u00e9clinique au d\u00e9veloppement clinique pr\u00e9coce. | \u00a9 Pilatus Biosciences\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain","description":"Pilatus Biosciences va \u00e9valuer le PLT012 en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/","og_locale":"fr_FR","og_type":"article","og_title":"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain","og_description":"Pilatus Biosciences va \u00e9valuer le PLT012 en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1.","og_url":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-08-20T13:19:16+00:00","article_modified_time":"2025-08-20T13:29:55+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain","datePublished":"2025-08-20T13:19:16+00:00","dateModified":"2025-08-20T13:29:55+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/"},"wordCount":388,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","keywords":["Biotech","Healthcare","R&amp;D","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/","url":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/","name":"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","datePublished":"2025-08-20T13:19:16+00:00","dateModified":"2025-08-20T13:29:55+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Pilatus Biosciences va \u00e9valuer le PLT012 en combinaison avec l\u2019atezolizumab de Roche dans un essai de Phase 1.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","width":1180,"height":811,"caption":"Ce nouvel essai clinique marque une \u00e9tape importante pour Pilatus Biosciences, qui fait progresser les immunoth\u00e9rapies de nouvelle g\u00e9n\u00e9ration de la recherche pr\u00e9clinique au d\u00e9veloppement clinique pr\u00e9coce. | \u00a9 Pilatus Biosciences"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-lance-son-premier-essai-clinique-chez-lhumain\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Pilatus Biosciences lance son premier essai clinique chez l\u2019humain"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=35143"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35143\/revisions"}],"predecessor-version":[{"id":35145,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35143\/revisions\/35145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/35147"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=35143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=35143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=35143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}